# Immune Disorder HSCT Protocol

> **NCT01821781** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 20 (estimated)

## Conditions studied

- Immune Deficiency Disorders
- Severe Combined Immunodeficiency
- Chronic Granulomatous Disease
- X-linked Agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Hyper-IgM
- DiGeorge Syndrome
- Chediak-Higashi Syndrome
- Common Variable Immune Deficiency
- Immune Dysregulatory Disorders
- Hemophagocytic Lymphohistiocytosis
- IPEX
- Autoimmune Lymphoproliferative Syndrome
- X-linked Lymphoproliferative Syndrome

## Interventions

- **DRUG:** Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan

## Key facts

- **NCT ID:** NCT01821781
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-04-29
- **Primary completion:** 2025-04-25
- **Final completion:** 2026-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01821781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01821781, "Immune Disorder HSCT Protocol". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01821781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*